When the US Food and Drug Administration approved a costly new drug for Alzheimer’s disease, Aduhelm, earlier this year, experts warned that all of Medicare’s more than 63 million enrollees could wind up paying the price.
When the US Food and Drug Administration approved a costly new drug for Alzheimer’s disease, Aduhelm, earlier this year, experts warned that all of Medicare’s more than 63 million enrollees could wind up paying the price.